Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1993 Jul;37(7):1539–1542. doi: 10.1128/aac.37.7.1539

Suramin prevents duck hepatitis B virus infection in vivo.

W B Offensperger 1, S Offensperger 1, E Walter 1, H E Blum 1, W Gerok 1
PMCID: PMC188009  PMID: 8363388

Abstract

The effect of suramin on duck hepatitis B virus (DHBV) infection was investigated in vivo. Suramin pretreatment of Pekin ducklings completely prevented DHBV infection. In contrast, suramin given at the time of or after inoculation with DHBV did not inhibit viral infection, replication, or gene expression. These data indicate that suramin effectively blocks the early stages of DHBV infection in vivo.

Full text

PDF
1539

Images in this article

1540Image
on p.1540
1541Image
on p.1541
1541Image
on p.1541

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Broder S., Yarchoan R., Collins J. M., Lane H. C., Markham P. D., Klecker R. W., Redfield R. R., Mitsuya H., Hoth D. F., Gelmann E. Effects of suramin on HTLV-III/LAV infection presenting as Kaposi's sarcoma or AIDS-related complex: clinical pharmacology and suppression of virus replication in vivo. Lancet. 1985 Sep 21;2(8456):627–630. doi: 10.1016/s0140-6736(85)90002-9. [DOI] [PubMed] [Google Scholar]
  2. Collins J. M., Klecker R. W., Jr, Yarchoan R., Lane H. C., Fauci A. S., Redfield R. R., Broder S., Myers C. E. Clinical pharmacokinetics of suramin in patients with HTLV-III/LAV infection. J Clin Pharmacol. 1986 Jan;26(1):22–26. doi: 10.1002/j.1552-4604.1986.tb02897.x. [DOI] [PubMed] [Google Scholar]
  3. De Clercq E. Suramin: a potent inhibitor of the reverse transcriptase of RNA tumor viruses. Cancer Lett. 1979 Nov;8(1):9–22. doi: 10.1016/0304-3835(79)90017-x. [DOI] [PubMed] [Google Scholar]
  4. Eisen V., Loveday C. Effects of suramin on complement, blood clotting, fibrinolysis and kinin formation. Br J Pharmacol. 1973 Dec;49(4):678–687. doi: 10.1111/j.1476-5381.1973.tb08544.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Hensey C. E., Boscoboinik D., Azzi A. Suramin, an anti-cancer drug, inhibits protein kinase C and induces differentiation in neuroblastoma cell clone NB2A. FEBS Lett. 1989 Nov 20;258(1):156–158. doi: 10.1016/0014-5793(89)81639-4. [DOI] [PubMed] [Google Scholar]
  6. Hosang M. Suramin binds to platelet-derived growth factor and inhibits its biological activity. J Cell Biochem. 1985;29(3):265–273. doi: 10.1002/jcb.240290310. [DOI] [PubMed] [Google Scholar]
  7. LOMINSKI I., GRAY S. Inhibition of lysozyme by 'Suramin'. Nature. 1961 Nov 18;192:683–683. doi: 10.1038/192683a0. [DOI] [PubMed] [Google Scholar]
  8. LaRocca R. V., Cooper M. R., Uhrich M., Danesi R., Walther M. M., Linehan W. M., Myers C. E. Use of suramin in treatment of prostatic carcinoma refractory to conventional hormonal manipulation. Urol Clin North Am. 1991 Feb;18(1):123–129. [PubMed] [Google Scholar]
  9. Lambeir A. M., Loiseau A. M., Kuntz D. A., Vellieux F. M., Michels P. A., Opperdoes F. R. The cytosolic and glycosomal glyceraldehyde-3-phosphate dehydrogenase from Trypanosoma brucei. Kinetic properties and comparison with homologous enzymes. Eur J Biochem. 1991 Jun 1;198(2):429–435. doi: 10.1111/j.1432-1033.1991.tb16032.x. [DOI] [PubMed] [Google Scholar]
  10. Leff P., Wood B. E., O'Connor S. E. Suramin is a slowly-equilibrating but competitive antagonist at P2x-receptors in the rabbit isolated ear artery. Br J Pharmacol. 1990 Nov;101(3):645–649. doi: 10.1111/j.1476-5381.1990.tb14134.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Mason W. S., Seal G., Summers J. Virus of Pekin ducks with structural and biological relatedness to human hepatitis B virus. J Virol. 1980 Dec;36(3):829–836. doi: 10.1128/jvi.36.3.829-836.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Mitsuya H., Popovic M., Yarchoan R., Matsushita S., Gallo R. C., Broder S. Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III. Science. 1984 Oct 12;226(4671):172–174. doi: 10.1126/science.6091268. [DOI] [PubMed] [Google Scholar]
  13. Offensperger W. B., Offensperger S., Walter E., Blum H. E., Gerok W. Inhibition of duck hepatitis B virus infection by lysosomotropic agents. Virology. 1991 Jul;183(1):415–418. doi: 10.1016/0042-6822(91)90157-7. [DOI] [PubMed] [Google Scholar]
  14. Offensperger W. B., Offensperger S., Walter E., Blum H. E., Gerok W. Sulfated polyanions do not inhibit duck hepatitis B virus infection. Antimicrob Agents Chemother. 1991 Nov;35(11):2431–2433. doi: 10.1128/aac.35.11.2431. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Offensperger W. B., Walter E., Offensperger S., Zeschnigk C., Blum H. E., Gerok W. Duck hepatitis B virus: DNA polymerase and reverse transcriptase activities of replicative complexes isolated from liver and their inhibition in vitro. Virology. 1988 May;164(1):48–54. doi: 10.1016/0042-6822(88)90618-6. [DOI] [PubMed] [Google Scholar]
  16. Petcu D. J., Aldrich C. E., Coates L., Taylor J. M., Mason W. S. Suramin inhibits in vitro infection by duck hepatitis B virus, Rous sarcoma virus, and hepatitis delta virus. Virology. 1988 Dec;167(2):385–392. [PubMed] [Google Scholar]
  17. Stein C. A., LaRocca R. V., Thomas R., McAtee N., Myers C. E. Suramin: an anticancer drug with a unique mechanism of action. J Clin Oncol. 1989 Apr;7(4):499–508. doi: 10.1200/JCO.1989.7.4.499. [DOI] [PubMed] [Google Scholar]
  18. Tsiquaye K. N., Collins P., Zuckerman A. J. Antiviral activity of the polybasic anion, suramin and acyclovir in Hepadna virus infection. J Antimicrob Chemother. 1986 Oct;18 (Suppl B):223–228. doi: 10.1093/jac/18.supplement_b.223. [DOI] [PubMed] [Google Scholar]
  19. Tsiquaye K., Zuckerman A. Suramin inhibits duck hepatitis B virus DNA polymerase activity. J Hepatol. 1985;1(6):663–669. doi: 10.1016/s0168-8278(85)80009-x. [DOI] [PubMed] [Google Scholar]
  20. Tuttleman J. S., Pugh J. C., Summers J. W. In vitro experimental infection of primary duck hepatocyte cultures with duck hepatitis B virus. J Virol. 1986 Apr;58(1):17–25. doi: 10.1128/jvi.58.1.17-25.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Walter E., Blum H. E., Meier P., Huonker M., Schmid M., Maier K. P., Offensperger W. B., Offensperger S., Gerok W. Hepatocellular carcinoma in alcoholic liver disease: no evidence for a pathogenetic role of hepatitis B virus infection. Hepatology. 1988 Jul-Aug;8(4):745–748. doi: 10.1002/hep.1840080407. [DOI] [PubMed] [Google Scholar]
  22. de Duve C., de Barsy T., Poole B., Trouet A., Tulkens P., Van Hoof F. Commentary. Lysosomotropic agents. Biochem Pharmacol. 1974 Sep 15;23(18):2495–2531. doi: 10.1016/0006-2952(74)90174-9. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES